Option Care Health Reports Mixed Q1 Results, Updates 2026 Gross Profit Outlook, and Expands Credit Facility
OPCH is trading near its 52-week low of $18.01 (12% above the low) on elevated volume (8.5× avg).
Summary
Option Care Health reported mixed Q1 2026 results with slow revenue growth and declining profitability, alongside a new $55 million negative gross profit outlook for 2026. The company significantly increased its revolving credit facility by $450 million, boosting liquidity.
Key Events · Earnings and Guidance · OPCH
-
Mixed Q1 2026 Financial Performance
Net revenue increased by 1.3% to $1.35 billion, but gross profit decreased by 0.4% to $262.0 million, and operating income fell by 8.4% to $72.5 million compared to Q1 2025. Net income declined by 3.0% to $45.3 million, though diluted EPS slightly increased to $0.29 due to fewer shares outstanding.
-
Updated 2026 Gross Profit Outlook
Management now anticipates a negative impact of approximately $55 million on 2026 gross profit, primarily driven by dynamics within the chronic inflammatory disease (CID) portfolio, including increased patient attrition and unfavorable therapy mix.
-
Expanded Revolving Credit Facility
The company increased its revolving credit commitments by $450 million, bringing the aggregate capacity to $850 million. As of March 31, 2026, $846 million was available for borrowing, significantly enhancing liquidity.
-
Reduced Share Repurchase Activity
Option Care Health repurchased $17.5 million of common stock in Q1 2026, a substantial decrease from $100.0 million in Q1 2025. The company still has $675.0 million remaining under its $1.0 billion share repurchase authorization.
Analysis · OPCH · Industrial Applications And Services
Option Care Health's first-quarter 2026 results, detailed in this 10-Q, confirm the mixed performance previously indicated by an 8-K filed on the same day. While net revenue saw modest growth, gross profit and operating income declined, and the company experienced increased cash outflow from operations. A significant new detail is management's expectation of a $55 million negative impact on 2026 gross profit due to shifts in the chronic inflammatory disease (CID) portfolio. This operational headwind is a key concern for investors. However, the company substantially bolstered its liquidity by increasing its revolving credit facility by $450 million to an aggregate of $850 million, providing significant financial flexibility. Share repurchase activity slowed considerably compared to the prior year, and the CEO and COO adopted routine 10b5-1 selling plans.
At the time of this filing, OPCH was trading at $20.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $18.01 to $36.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.